Flagship‑backed Lila Sciences expanded its Series A with a $115 million extension after an initial $235 million close, bringing total Series A proceeds to $350 million; the extension included investment from Nvidia’s venture arm. Lila positions itself at the intersection of AI and life sciences, aiming to connect advanced models to experimental platforms and real‑world biology. The company markets an audacious vision of “scientific superintelligence” to accelerate discovery across molecular design and biology. Nvidia’s participation signals continued investor interest in startups that tightly couple model scale with laboratory execution and bespoke compute infrastructure. The funding will expand Lila’s roadmap for AI‑driven molecular design, recruit talent, and scale compute and wet‑lab integration to validate model predictions at pace.